announc
end
sever
acut
respiratori
syndrom
sar
epidem
juli
new
communityacquir
case
sar
report
decemb
januari
guangzhou
citi
provinc
guangdong
china
genom
sequenc
sarsassoci
coronaviru
sarscov
isol
recov
index
case
patient
sar
palm
civet
associ
sar
outbreak
nearli
ident
result
phylogenet
analysi
combin
epidemiolog
lineag
inform
suggest
sarscov
reintroduc
human
anim
although
report
none
patient
involv
secondari
spread
symptomat
sarscov
infect
describ
patient
asymptomat
sarscov
infect
identifi
contact
index
case
patient
commun
outbreak
asymptomat
case
sarscov
infect
confirm
sensit
method
viral
antigen
detect
serolog
test
asymptomat
case
also
highlight
issu
associ
diseas
prevent
present
studi
perform
retrospect
seventeen
serum
specimen
collect
index
case
patient
exhibit
recurr
sar
laboratoryconfirm
sarscov
infect
guangzhou
citi
china
decemb
januari
addit
serum
specimen
collect
contact
index
case
patient
sar
identifi
nucleocapsid
n
protein
sarscov
serum
specimen
antigencaptur
assay
perform
n
antigencaptur
elisa
n
antigencaptur
chemiluminesc
immunoassay
cia
develop
assay
base
detect
monoclon
antibodi
direct
n
protein
sarscov
describ
elsewher
serum
igg
igm
antibodi
sarscov
detect
use
commerci
avail
indirect
elisa
kit
bgigbi
biotech
accord
manufactur
instruct
sensit
specif
elisa
detect
igg
antibodi
sarscov
respect
sensit
specif
elisa
detect
igm
antibodi
sarscov
respect
indirect
immunofluoresc
assay
ifa
detect
igg
antibodi
sarscov
perform
use
commerci
avail
ifa
kit
euroimmun
accord
manufactur
instruct
ifa
specif
detect
igg
antibodi
sarscov
healthi
blood
donor
sensit
detect
igg
antibodi
sarscov
serum
specimen
obtain
least
day
onset
symptom
patient
sar
inhous
ifa
detect
igg
specif
human
coronavirus
perform
describ
us
elsewher
microneutr
assay
perform
accord
procedur
describ
elsewher
modif
brief
microtit
plate
contain
confluent
fetal
rhesu
cell
ml
mainten
medium
prepar
twofold
dilut
patient
serum
sampl
ml
start
increas
premix
ml
tcid
sarscov
isol
incub
h
ml
virusserum
mixtur
inocul
duplic
well
fetal
rhesu
cell
incub
cytopath
effect
observ
h
neutral
titer
determin
reciproc
highest
serum
dilut
produc
cytopath
effect
cell
neutral
antibodi
titer
consid
posit
sarscov
serum
specimen
test
n
protein
sarscov
use
n
antigencaptur
elisa
n
antigencaptur
cia
find
assay
valid
previous
use
serum
specimen
obtain
patient
serolog
confirm
sar
sensit
specif
n
antigencaptur
elisa
document
although
characterist
n
antigencaptur
cia
shown
equival
n
antigencaptur
elisa
data
shown
n
antigencaptur
cia
seem
sensit
n
antigencaptur
elisa
present
studi
n
antigencaptur
assay
detect
n
protein
serial
obtain
serum
specimen
collect
patient
day
onset
symptom
cia
also
abl
detect
n
protein
serum
sampl
collect
second
index
case
patient
ninth
day
onset
symptom
although
sampl
neg
result
accord
n
antigencaptur
elisa
tabl
result
surpris
enzymeamplifi
chemiluminesc
chemic
analysi
gener
sensit
convent
elisa
index
case
patient
first
serum
sampl
obtain
day
onset
symptom
n
protein
detect
serial
obtain
serum
specimen
patient
ill
serum
specimen
obtain
contact
index
case
patient
specimen
collect
januari
femal
contact
second
index
case
patient
experienc
onset
symptom
decemb
femal
contact
found
posit
n
protein
mean
n
antigencaptur
cia
presenc
sarscov
infect
confirm
serolog
test
tabl
ifa
detect
increas
sarscov
antibodi
titer
pair
serum
sampl
collect
period
igm
igg
antibodi
sarscov
also
detect
elisa
antibodi
sarscov
also
detect
convalescentphas
serum
sampl
obtain
femal
contact
case
patient
week
later
result
sarscov
microneutr
assay
also
found
posit
titer
determin
convalescentphas
serum
sampl
obtain
femal
contact
case
patient
serolog
result
verifi
center
diseas
control
prevent
guangzhou
one
sar
refer
laboratori
china
exclud
possibl
falseposit
result
serum
specimen
contact
case
patient
test
antibodi
human
coronavirus
use
ifa
pair
serum
sampl
show
increas
titer
antibodi
either
test
also
perform
serial
obtain
serum
specimen
index
case
patient
tabl
although
pair
serum
sampl
obtain
first
second
index
case
patient
show
increas
titer
antibodi
neutral
antibodi
detect
index
case
patient
previou
studi
although
none
index
case
patient
show
evid
secondari
spread
infect
direct
detect
sarscov
n
protein
highli
sensit
cia
serum
sampl
serial
dilut
b
highest
ratio
acutephas
convalescentphas
absorb
valu
serum
dilut
test
ill
case
first
confirm
document
asymptomat
case
sar
outbreak
asymptomat
case
infect
occur
woman
work
servic
chief
local
restaur
tdlr
second
index
case
patient
work
waitress
although
asymptomat
case
patient
indirect
contact
second
index
case
patient
histori
clear
close
anim
ie
palm
civet
contact
often
show
wild
anim
custom
order
exot
food
subsequ
sarscov
n
protein
detect
use
n
antigencaptur
elisa
total
palm
civet
serum
sampl
obtain
period
restaur
tdlr
result
reveal
high
level
n
protein
mean
od
valu
compar
cutoff
valu
viral
rna
also
detect
throat
rectal
swab
specimen
obtain
palm
civet
use
rtpcr
detect
polyprotein
n
gene
sarscov
full
genom
sequenc
complet
gene
sequenc
sarscov
identifi
specimen
obtain
palm
civet
inform
consid
togeth
viral
genom
inform
palm
civet
collect
restaur
period
clear
conclus
palm
civet
use
exot
food
restaur
must
heavili
contamin
sarscov
limit
sampl
avail
kinemat
antigenemia
antibodi
respons
second
index
case
patient
compar
asymptomat
case
patient
asymptomat
case
patient
antigenemia
ie
detect
n
antigen
serum
antigenemia
detect
asymptomat
case
patient
januari
disappear
almost
time
disappear
second
index
case
patient
detect
antigenemia
januari
meanwhil
second
index
case
patient
seroconvers
occur
januari
wherea
asymptomat
case
patient
posit
antibodi
result
januari
howev
serum
sampl
unavail
date
exact
date
seroconvers
determin
nevertheless
mean
incub
period
sar
day
seem
asymptomat
case
patient
unlik
acquir
infect
directli
second
cid
juli
che
et
al
index
case
patient
combin
epidemiolog
inform
regard
contact
histori
molecular
diagnost
profil
either
anim
palm
civet
human
second
index
case
patient
infer
asymptomat
case
sar
like
result
animaltohuman
infect
like
due
sarscov
carri
palm
civet
restaur
second
index
case
patient
sar
zoonot
diseas
sarscov
evolv
consist
rapidli
within
anim
human
host
infect
viru
sever
diseas
vari
along
variationadapt
viru
host
particularli
signific
even
earli
phase
sar
epidem
humantohuman
transmiss
infect
observ
symptom
sever
diseas
eventu
name
primari
symptomat
characterist
howev
commun
outbreak
sar
none
index
case
patient
confirm
sar
sever
ill
seem
acquir
infect
sarscov
directli
anim
although
sarscovspecif
antibodi
previous
detect
rel
high
rate
among
popul
handl
wild
anim
observ
health
care
worker
imposs
correl
serolog
result
correspond
onset
clinic
symptom
retrospect
screen
therefor
asymptomat
case
patient
describ
present
articl
first
patient
asymptomat
sarscov
infect
detect
antigenemia
seroconvers
caus
animaltohuman
infect
find
togeth
previous
report
find
serolog
analysi
handler
wild
anim
index
case
patient
commun
outbreak
sar
reveal
like
intermedi
epidemiolog
phase
might
critic
genet
adapt
viru
new
host
critic
mutat
enabl
eventu
caus
sever
symptomat
sar
seen
earli
although
usual
difficult
observ
viru
intermedi
phase
sarscov
one
rare
virus
genotyp
antigenantibodi
correspond
intermedi
phase
detect
find
may
also
signific
prevent
sar
epidem
although
contagi
human
epidem
strain
sarscov
middl
late
phase
pandem
seen
natur
sinc
june
risk
asymptomat
mildli
symptomat
infect
sarscov
ignor
date
molecular
epidemiolog
data
indic
although
might
take
decad
sarscov
evolv
contagi
strain
human
infect
would
difficult
sarscov
reach
stage
might
caus
infect
either
without
symptom
mild
symptom
human
process
could
acceler
appropri
suscept
anim
host
palm
civet
larg
present
togeth
human
popul
hand
highrisk
popul
infect
properli
monitor
asymptomat
stage
diseas
promptli
control
mildli
symptomat
stage
object
technic
feasibl
futur
threat
reemerg
sar
epidem
could
much
lower
surmis
